UNSPSC 51292607: Clorazepate monopotassium or potassium clorazepate

This classification denotes a benzodiazepine with the molecular structure C16H10CLN2O3.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, MS63G8NQUI chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt, but more commonly known as clorazepate monopotassium, which bears US NIH Compound Identifier 22312. European Medicines Agency schedules Clorazepate monopotassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01369MIG.

UNSPSC 51292607 Clorazepate monopotassium or potassium clorazepate (Commodity) encompasses pharmaceutical supply procurement by state and local health agencies, though recent opportunities under this code do not reflect purchases of clorazepate specifically. Instead, state and local buyers are soliciting naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). These procurements target public health interventions, employee health plans, and institutional pharmacy supply chains across participating jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The Seminole County Community Health Building issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—a discrepancy suggesting the posting date may be outdated. The Texas HHS Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, with no formal award timeline. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with contract effectiveness July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.